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Graft versus host disease (GVHD) is a common complication of allogeneic stem 
cell transplantation (allo-SCT). Ocular GVHD develops in approximately 40–60% 
of patients following allo-SCT and its most common clinical manifestations include 
keratoconjunctivitis sicca and cicatricial conjunctivitis. Ocular GVHD may lead to severe 
ocular surface disease, which can significantly diminish quality of life and restrict 
daily activities. It is thus important to monitor the condition closely since with timely 
diagnosis, irreversible damage can be avoided. The current review will focus on updated 
information regarding ocular GVHD.
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INTRODUCTION 
Hematopoietic stem cell transplantation (SCT), 
including bone marrow transplantation (BMT), 
peripheral blood stem cell transplantation 
and cord blood transplantation, is the routine 
treatment and a potential cure for life-
threatening hematologic malignancies, aplastic 
anemia, severe combined immunodeficiency, 
and certain metabolic diseases such as 
mucopolysaccharidoses and lysosomal storage 
disorders.1 Graft versus host disease (GVHD) 
remains one of the major complications of 
allogenic (allo-) SCT; the condition occurs in 
25-70% of patients and is responsible for non-
relapse mortality and morbidity in patients 
undergoing allo-SCT.2
According to the National Institutes of 
Health (NIH), GVHD can be classified into 
two broad categories.3 Acute GVHD (aGVHD) 
is an immediate multi-organ inflammatory 
syndrome primarily affecting the skin, liver and 
digestive tract. Chronic GVHD (cGVHD), which 
previously referred to instances developing 100 
days after transplantation, according to the new 
NIH classification has no time limit; it involves 
multiple systems such as the musculoskeletal 
and hematologic systems, as well as various 
organs including the skin, gut, lungs, and 
eyes. Clinical features are very complex; there 
are manifestations of mixed autoimmune/
collagen vascular diseases and the hallmarks are 
comprised of fibrosis, stenosis, and atrophy of 
tissues in the skin, lung, and mucous membranes Ocular GVHD; Nassiri et al
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such as in the mouth, vagina, and eyes.4
Ocular complications develop in a substantial 
percentage of patients after allo-SCT as part of 
acute or chronic GVHD. Ocular GVHD has the 
potential to lead to severe ocular problems, 
impair quality of life, and restrict daily activities, 
and thus, warrants close ophthalmic monitoring 
in patients undergoing allo-SCT.5 The current 
article will focus on updated information 
regarding ocular GVHD.
Pathophysiology
The complex interaction between donor T-cells 
and host tissues in aGVHD has been described as 
a three-step process that includes 1) damage to 
recipient tissue by the pre-transplant conditioning 
regimen, 2) donor T-cell activation caused by 
recipient antigen presentation followed by 
clonal expansion, and 3) cell death induced 
by activated T-cells, cytokines such as tumor 
necrosis factor-alpha (TNF-α), and other innate 
immune cells. In particular, the inflammatory 
process in aGVHD is thought to involve type 
1 T-helper cells, interleukin (IL)-2, interferon-γ 
(IFN-γ), and IL-1.6 In ocular aGVHD, such 
T-cell mediated processes are mainly detected 
in conjunctival and lacrimal gland tissues. In 
cases with pseudomembranous conjunctivitis, 
donor-derived mononuclear T lymphocytes, 
and fibrinoid material with cellular debris and 
inflammatory cells have been observed.7
The pathophysiology of cGVHD is less 
understood. The hallmark is IFN-γ expression, 
and in light of distinctive similarities, especially 
with collagen vascular disorders, it is often 
considered an autoimmune disease. There is 
excessive fibrosis, collagen deposition, antibody 
production, and suppression of the acute 
inflammatory response.8 In animal models of 
cGVHD, type 2 T-helper cells produce cytokines 
such as IL-4, IL-10, transforming growth factor-β1 
and IFN-γ in the absence of IL-2.9 Contrary to 
aGVHD, donor antigen-presenting cells play a 
role in the pathogenesis of the chronic form of 
the disease.10
The eye is a target organ for GVHD, and 
the ocular surface shows major changes even in 
the absence of dry eye.11 Ocular involvement in 
cGVHD appears as inflammatory destruction of 
the conjunctiva and lacrimal glands with fibrosis, 
decreased goblet cell density, and a resultant 
decrease in tear production.12 Tear physiology is 
found to be severely impaired in most aspects, and 
compared to Sjögren’s syndrome and meibomian 
gland dysfunction, tear turnover rate is lowest, 
evaporation and osmolarity are highest, and the 
lipid layer appears the most unstable.13
Late ocular complications following BMT 
include retinal lesions and cataracts as well. 
The retinal microvasculopathy seen with 
GVHD seems to reflect a generalized process, 
and similar to cataract formation, is attributed 
to other factors such as the use of steroids, 
irradiation, and systemic hypertension.14
Prevalence and Risk Factors
Ocular GVHD develops in 40-60% of patients 
after allo-SCT, and 60-90% of patients with 
acute or chronic GVHD.10 Although signs and 
symptoms such as photophobia, hyperemia, 
hemorrhagic conjunctivitis, pseudomembrane 
formation, lagophthalmos, and corneal 
ulceration may occur as early as 50 days during 
the course of aGVHD, ocular GVHD is mainly 
associated with, and more severe in, cGVHD and 
occurs in 40-60% of such cases.5 While ocular 
symptoms may be the first manifestation of 
systemic GVHD, the presence of skin and/or 
mouth involvement puts patients at a higher 
risk for ocular GVHD.15 A higher risk was also 
detected in patients with allo-SCT from related 
donors compared to those receiving transplants 
from matched unrelated donors, probably due 
to conditioning with anti-thymocyte globulins 
in the latter group. The choice of stem cell 
source has shown no clear association with the 
development of ocular GVHD.5
Manifestations
Ocular tissues affected by acute and chronic 
forms of GVHD include the eyelid and 
periorbital skin, conjunctiva, cornea, lens, 
lacrimal system, sclera, uvea, and retina. While 
certain complications such as dry eye are very 
common and are used for diagnosis, scoring, and Ocular GVHD; Nassiri et al
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prognosis assessment of GVHD, some occur less 
frequently. Nonetheless, many ocular symptoms 
can be the first and only presentation of ocular 
GVHD, and some have the potential to progress 
to severe ocular conditions such as corneal 
ulceration, melting, and perforation which may, 
on occasion, lead to evisceration.12 Thus, close 
monitoring and timely diagnosis are necessary 
to avoid such drastic complications that can 
permanently impair vision and quality of life.
Ocular Surface Manifestations
Ocular surface and corneal complications of GVHD 
can be the direct result of conjunctival goblet cell 
involvement, or an indirect outcome of lacrimal 
gland stasis caused by immunosuppression or 
total body irradiation.12 Major findings in the 
conjunctiva and cornea include keratinization, 
epithelial thinning, and squamous metaplasia.5
Dry Eye
Dry eye syndrome (DES) or keratoconjunctivitis 
sicca is the most frequent complication of 
GVHD, and is reported to occur in 40 to 76% of 
patients.4,5,12,15 It may be the initial presentation 
and sole complication of GVHD and may occur 
in the absence of other systemic complications.10 
While the main cause of DES is cGVHD, other 
reasons such as irradiation, chemotherapy, 
immuno-suppressive therapy, and infection can 
contribute as well. Other risk factors, especially 
for severe dry eye, include meibomian gland 
disease and female to male BMT.16 Dry eye can 
develop any time from a few weeks up to 100 
months after transplantation, and the median 
time is usually around 6 months.12
Subjective symptoms of dry eye are 
the hallmark of this disease. Patients most 
commonly experience dry eye and foreign 
body sensation followed by ocular fatigue, 
discharge, and dull sensations.17 In the majority 
of patients, symptoms progress to severe dry eye 
resembling Sjögren syndrome. Other symptoms 
include burning, stinging, itching, soreness and 
heaviness of the eyelids, and photophobia.4,5,12,15 
Table 1 contains DES symptom classification 
used for cGVHD scoring. 
Conjunctival Disease
Conjunctival involvement in GVHD can be seen 
in about 10% of cases and is often indicative of 
severe systemic involvement.18 Acute GVHD that 
involves significant conjunctival inflammation 
and sloughing typically leaves behind sequelae 
such as conjunctival scarring and symblepharon. 
These cicatricial changes can further progress 
during the course of chronic GVHD. Cases of 
conjunctival chemosis with multiple central serous 
chorioretinopathy lesions occurring as early as 
day 16 and scleritis with choroidal detachment 
on day 40 have also been described.18 The severity 
GVHD score Ocular symptom
Dry eye syndrome
0 No dry eye symptoms
1 Dry eye symptoms not affecting activities of daily living 
(eye drops ≤3 per day) or asymptomatic signs of keratoconjunctivitis sicca
2 Dry eye symptoms partially affecting activities of daily living 
(eye drops >3 per day or punctal plugs) without vision impairment
3 Dry eye symptoms, significantly affecting activities of daily living 
(special eyewear to relieve pain) or unable to work because of ocular symptoms or loss of 
vision caused by keratoconjunctivitis sicca
Conjunctivitis
0 None
1 Conjunctival hyperemia
2 Conjunctival hyperemia with chemotic response and serosanguinous exudate
3 Pseudomembranous conjunctivitis
4 Pseudomembranous conjunctivitis with corneal epithelial sloughing and subsequent 
conjunctival scar and symblepharon formation
Cataract
1 Occasional subcapsular opacities and vacuoles in the central region of the lens
2 Small clusters of subcapsular opacities remaining discrete
3 Multiple clusters of subcapsular opacities that have mostly coalesced
Table 1. Grading ocular symptoms in graft versus host disease (GVHD)Ocular GVHD; Nassiri et al
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of symptoms at this stage does not necessarily 
correlate with the clinical presentation. 
Cataract
Cataract formation is a common late complication 
of allo-SCT (Table 1). It is mainly attributed 
to irradiation and steroid therapy, and is the 
most common cause of visual acuity loss among 
patients.12,15,18 Patients receiving total body 
irradiation are at higher risk of developing 
cataracts than recipients of fractionated total 
body irradiation (83% vs. 21% at 6 years); it tends 
to develop much earlier in the former group as 
well. Nonetheless, most surviving patients will 
eventually require cataract surgery.12,15,18
Other Findings
Other ocular manifestations of GVHD include 
cutaneous complications such as eyelid 
dermatitis, lagophthalmos and ectropion, poliosis, 
madarosis, and vitiligo.12,15 Uveitis can occur in 
up to 8% of cases with cGVHD, and it is important 
to distinguish infectious etiologies or neoplastic 
masquerade syndrome from noninfectious 
uveitis.12 Neuro-ophthalmologic complications 
such as disc edema are likely secondary to the 
toxic effects of chemotherapeutic agents such 
as cyclosporine A and/or coexisting medical 
conditions, and are usually reversible.19 The main 
vitreoretinal complication seen in association 
with GVHD is retinal microvasculopathy that 
may occur in 10% of cases. Findings include optic 
disc edema, cotton-wool spots in the fundus, 
intraretinal and vitreous hemorrhage, and lipid 
deposits.19 Posterior segment complications also 
include infections such as infectious retinitis 
from cytomegalovirus (CMV), herpes simplex 
virus, or varicella zoster virus, central serous 
chorioretinopathy and posterior scleritis.10,12,15
Diagnosis and Grading
The diverse range of ocular complications of 
GVHD calls for close monitoring, assessment 
of symptoms, and comprehensive ophthalmic 
examinations including visual acuity testing, slit 
lamp examination, dry eye workup, tonometry, 
and fundoscopy. In addition to manifestations 
and test results, the diagnosis of ocular GVHD 
can be made through conjunctival biopsies. 
The clinical diagnosis of the most common 
ocular complication, i.e. DES, is not always 
straightforward. A combination of history 
taking and medical examination must be used 
because some patients may have significant 
symptoms with few findings, whereas others 
have significant clinical findings with only mild 
symptoms. After obtaining a thorough history, 
a careful examination is important to make the 
diagnosis of dry eye and determine the most 
likely etiology. There are a number of diagnostic 
tests for dry eye, which can be divided into four 
general categories including tear film stability, 
ocular surface health, tear film composition, and 
tear film flow.
Prophylaxis and Treatment
At present, aGVHD prophylaxis is mainly 
attempted by immunosuppression with drugs 
such as methotrexate, cyclosporine and anti-
lymphocyte antibodies. Some studies have 
reported that combination therapy is more 
successful.20,21  Immunosuppressive drugs 
and steroids are used to prevent cGVHD, 
nonetheless, results are not satisfactory. As for 
ocular GVHD, cyclosporine eye drops appear to 
have a prophylactic effect.12,20 As a preventive 
measure against cataract, eye shielding during 
total body irradiation can delay its development 
and decrease its severity.22
Treatment of GVHD mainly constitutes 
immunosuppressive therapy, and there are 
guidelines for monitoring and treatment of organ-
specific symptoms and complications.23 In ocular 
GVHD, most treatments are aimed at relieving 
DES by supporting the tear film, controlling 
inflammation, and maintaining mucosal 
integrity. To date, there have been no controlled 
trials for ocular GVHD treatment options; these 
have mostly provided unsatisfactory results 
and include a variety of topical, systemic, and 
surgical approaches, as well as eyewear and 
environmental strategies that are administered 
with respect to the severity of the condition. 
Treatment recommendations according to Ocular GVHD; Nassiri et al
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severity are summarized in Table 2.24 As with 
any other organ, the first level should include 
patient education and counseling. At this level, 
environmental management includes use of 
humidifiers and lower room temperatures. At 
higher levels, while priority is given to topical 
options, systemic therapy may be needed when 
the eye is resistant or when other organs are 
involved. 
Tear function can be improved by controlling 
lubrication, evaporation, and drainage. The 
most common approach is instilling artificial 
tears, which are available in different brands; 
their efficacy may be comparable and patients 
should use the ones they tolerate best. Artificial 
tears decrease symptoms and improve vision 
by coating the ocular surface and minimizing 
punctate keratopathy.25 Autologous serum eye 
drops are especially beneficial for patients with 
DES due to GVHD and are now recommended 
to be used earlier in the course of the disease. 
Wearing eye protection such as moisture 
chamber goggles can help decrease evaporation. 
One of the most exciting new treatments that is 
useful for recalcitrant cases are contact lenses. 
Special contact lenses including soft and hard 
scleral lenses have been shown to be safe and 
effective in moderate to severe cases, and may 
help reduce patient dependency on lubricants, 
minimize symptoms, and improve quality of 
life.12,26 Prosthetic Replacement of the Ocular 
Surface Ecosystem (PROSE) is one of the exciting 
new treatments (Fig. 1). It has been developed 
by the Boston Foundation for Sight (Needham, 
MA, USA) to restore vision, support healing, 
reduce symptoms, and improve quality of 
life for patients experiencing complex corneal 
diseases, including irregular astigmatism and 
ocular surface disease. PROSE uses Food and 
Drug Administration (FDA) approved custom 
designed and fabricated prosthetic devices to 
replace or support impaired ocular surface 
system functions that protect and enable vision. 
The fluid-ventilated gas-permeable prosthetic 
devices clear the cornea and immerse the entire 
ocular surface in a reservoir of artificial tears. 
Device design features an optic portion linked 
to a customized bearing haptic portion, which is 
designed to align with the sclera. Oxygenation of 
the fluid-filled reservoir is principally maintained 
by oxygen transmission through the prosthetic 
material, but there is some oxygen supplied 
through tear-fluid exchange under the haptic 
region. PROSE treatment replaces the functions 
of the ocular surface system by creating a smooth 
optical surface over an irregular, damaged, or 
diseased cornea. It also provides an expanded 
artificial tear reservoir that yields constant 
lubrication, while maintaining necessary oxygen 
supply. Successful treatment re-establishes a 
healthy and stable ocular surface environment 
that supports healing, reduces symptoms, and 
also improves visual function. The lens also 
Level Recommended measure
1 Education and counseling
Environmental management
Elimination of offending systemic medications
Preserved tear substitutes, allergy eye drops
2 Unpreserved tears, gels, ointments
Steroids
Cyclosporine A
Secretagogues
Nutritional supplements
3 Tetracyclines
Autologous serum tears
Punctal plugs (after control of inflammation)
4 Topical vitamin A
Contact lenses
Acetylcysteine
Moisture goggles
Surgery
Table 2. Treatment recommendations for dry eye based 
on severity; should treatment outcome at any given level 
be unsatisfactory, suggested measures of the next level 
are added
Figure 1. A Prosthetic Replacement of the Ocular Surface 
Ecosystem (PROSE) lens fitted over the eye of a patient 
with severe dry eye due to chronic graft versus host 
disease.Ocular GVHD; Nassiri et al
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acts to mask surface corneal irregularities and 
prevents damage by protecting and shielding the 
cornea and conjunctiva against the environment 
and eyelids.27,28 In a study, PROSE significantly 
mitigated symptoms and improved quality of life 
in patients with severe dry eye from cGVHD.26
The first line treatment in order to control 
ocular surface inflammation is topical steroids, 
as they exert non-specific inhibitory effects on 
the inflammatory response and can improve DES 
signs and symptoms. However, although some 
preparations such as loteprednol etabonate are 
relatively safer, they are more or less associated 
with an increased risk of infection, glaucoma, 
and cataract;29 therefore, they are recommended 
for pulse therapy with close monitoring rather 
than long-term treatment. The immune response 
is commonly controlled with cyclosporine eye 
drops which inhibit T-cell activation, down-
regulate pro-inflammatory cytokines, increase 
the number and density of conjunctival goblet 
cells, and minimize signs and symptoms of DES 
with minimal side effects.30,31 Cases unresponsive 
to a twice daily regimen of cyclosporine 0.05% 
may benefit from more frequent administration 
of the medication.32 Topical vitamin A (retinyl 
palmitate) and topical retinoic acid are also 
helpful; the former has been found to be 
comparable to cyclosporine A 0.05% eye drops 
in the management of DES.33 
Another exciting new treatment for 
management of ocular surface disease in patients 
with GVHD is autologous serum drops. Treatment 
with autologous plasma rich in platelet-derived 
growth factor has shown an 80% success rate 
in refractory cases of cGVHD-related DES.34 It 
is generally advised to administer autologous 
tear drops to these patients with even milder 
symptoms of dry eye (Fig. 2). If topical therapy 
proves insufficient for controlling ocular surface 
inflammation, systemic immunosuppression 
should be started or increased in consultation 
with the hematologist/oncologist.35-39
Surgical management of DES includes 
punctal occlusion which is recommended for 
all patients early in the course once the ocular 
surface inflammation has been controlled. Partial 
tarsorrhaphy would be considered as a last resort 
option for patients with recurrent epithelial 
breakdown; however specialty contact lenses 
would be preferred over tarsorrhaphy. If severe 
complications such as corneal perforation ensue, 
multilayer amniotic membrane transplantation 
and keratoplasty may be required (along with 
tarsorrhaphy).12
Other manifestations of ocular GVHD 
should be treated accordingly. Conjunctival 
inflammation can be relieved using topical 
steroids such as prednisolone acetate 1%. Surgical 
approaches in this regard include superficial 
debridement of filamentary keratitis and removal 
of pseudomembranes. Complications such as 
uveitis should respond to topical and systemic 
medications administered to control GVHD, 
and posterior scleritis has been successfully 
treated with systemic corticosteroids and 
acetazolamide.40 The treatment for cataract is 
surgical, and when performed in GVHD patients, 
special attention should be given to maintaining 
normal tear physiology.12 It should be noted 
that most of these patients will typically have 
worsening of DES immediately after cataract 
surgery. Therefore, the dry eye should be fully 
controlled prior to cataract surgery.
Prognosis
GVHD following allo-SCT often has poor 
prognosis; ten-year, non-relapse survival rates 
range from 4 to 91% depending on severity. 
With cGVHD, the 2-year overall survival for 298 
patients with mild, moderate and severe disease 
Figure 2. Severe corneal and conjunctival staining in a 
patient with chronic ocular graft versus host disease; this 
patient was started on autologous serum tears resulting 
in significant improvement of signs and symptoms.Ocular GVHD; Nassiri et al
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was 97%, 86%, and 62% respectively.41 The long-
term impact of ocular GVHD on quality of life has 
not yet been systematically studied. Balaram et al 
followed 114 patients for more than 1 year after 
SCT and concluded that late-onset ocular surface 
disease can occur, and thus the need for long-term 
monitoring should not be neglected.42 Data on 
the long-term clinical course and visual outcomes 
of patients with ocular GVHD are required in 
order to determine prognostic indicators, develop 
appropriate measures and therapeutic guidelines, 
and also improve outcomes.
In conclusion, ocular GVHD is a common 
manifestation of hematopoietic allo-SCT which 
can result in significant morbidity and decreased 
quality of life, severe ocular surface disease and 
in some cases significant corneal complications. 
Treatment may require multiple strategies 
including topical and oral medications, surgical 
approach, environmental control and systemic 
immunosuppression. New therapies including 
autologous serum tears and scleral lenses have 
provided treatment options for management 
of ocular GVHD. More data on the impact of 
ocular GVHD, in addition to development of 
therapeutic and preventive measures are needed.
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